Jagmohan Hooda

The paper develops a novel mouse cell line model of invasive lobular breast carcinoma that recapitulates human tumor phenotype and immune microenvironment, offering a preclinical platform for therapy evaluation.

This study shows that chronic inflammation and hormonal changes in older women create a tumor-permissive environment for ER+ breast cancer by increasing local estradiol and immune dysfunction.

This study shows HER2 mutations drive HER2/HER3 hyperactivation in ILC, making it sensitive to HER2/HER3-targeting ADCs, and highlights the synergy between T-DXd and P-DXd.

This study shows that ER-positive ILC xenograft models replicate metastatic patterns and endocrine response of human invasive lobular breast carcinoma.

This study shows that restoring E-cadherin in ILC models reduces metastasis to specific organs but has limited effects on primary tumor growth and 2D cell growth.

This study identifies and characterizes patient-derived xenograft models of invasive lobular breast carcinoma using multi-omics and histopathology, finding seven ILC PDX models with CDH1 mutations and low CDH1 expression.

This study identifies RET as a druggable target in estrogen receptor-positive breast cancer brain metastases and shows that Pralsetinib inhibits RET-driven metastatic properties.

This study shows ER fusion proteins in breast cancer cell lines drive ligand-independent pro-oncogenic pathways, with subtype- and fusion-specific effects.

The paper characterizes ILC and ILC-like cell lines through multi-omic analysis to identify molecular similarities with patient tumors and potential therapeutic targets.

The paper introduces a new invasive lobular carcinoma cell line, WCRC-25, and demonstrates its molecular features and therapeutic response to PI3K/AKT inhibition.